Sean Zhang, Ph.D.

Sean Zhang, Ph.D. is a Principal at Vivo Capital. Prior to Vivo, he was a Vice President at Lilly Asia Ventures , where he focused on biotech venture capital investments and new company incubation. Prior to that, Sean was a management consultant at McKinsey & Company, and provided strategic consulting to pharmaceutical and biotech companies on areas such as R&D strategy, sales & marketing, and due diligence. He also has hands-on experience working at biotech companies such as Ocelot Bio and Allele Biotech. Sean currently serves as a member of the Board of Directors of Rgenta Therapeutics, and board observer at Zenas Biopharma. He previously served on the board of directors of ADARx Pharmaceuticals, Perfuse Therapeutics, and Proteologix.

Sean received his Ph.D. in Molecular Biology at University of Pittsburgh School of Medicine, and B.E. of bioengineering at Xi’an Jiaotong University. Additionally, he completed his postdoctoral training at the University of California San Diego.